Which diabetes drug wins? new study pits dapagliflozin vs empagliflozin
NCT ID NCT07311551
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two common diabetes drugs, dapagliflozin and empagliflozin, to see which works better for lowering blood sugar and weight in people with type 2 diabetes and a high body mass index. About 112 adults will take one of the two drugs for six months. Researchers will also check safety, liver and kidney function, blood pressure, and cost to help doctors choose the best option.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Blood test could predict who faces rapid kidney decline in diabetes
- Blood test may predict kidney decline in diabetes — a large trial investigates
- Hormone clue may unmask kidney danger in diabetes
- Can a single pill tackle both fatty liver and diabetes?
- Does when you eat carbs and protein reshape blood sugar control?